ClinicalTrials.gg
Sign In
RecruitingNCT02753335Updated Oct 8, 2026

Clinical and Cerebral Changes Following Multifaceted Rehabilitation of Complex Regional Pain Syndrome

An interventional study of Individualized CRPS Rehabilitation in Complex Regional Pain Syndrome (CRPS), sponsored by University Hospital of North Norway. Recruiting at 1 site in Norway. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by University Hospital of North Norway · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2016; still recruiting 10 years 2 months later.
Updated Oct 8, 2026Primary completion movedStudy completion moved+7 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study investigates the clinical effects of an individually tailored rehabilitation program for patients with Complex Regional Pain Syndrome (CRPS). A randomized multiple-baseline single-case experimental design (SCED) will be used to evaluate individual changes in CRPS interference with daily activities, pain, and limb function during rehabilitation. Treatment components will be adjusted according to each participant's needs and response to treatment. The study will also use magnetic resonance imaging (MRI) to investigate brain structure in patients with CRPS compared with healthy controls and to examine whether brain structure changes over time in patients with CRPS.

Read the detailed description

The study comprises two complementary work packages (WPs).

Work Package 1 (WP1) uses a prospective randomized multiple-baseline single-case experimental design (SCED) to evaluate the rehabilitation process and clinical effects in individual participants with Complex Regional Pain Syndrome (CRPS). Participants are randomized to a baseline duration of 2, 3, or 4 weeks before the intervention is introduced. The rehabilitation combines Graded Motor Imagery (GMI) and tactile desensitization (TD) within a Psychologically Informed Care (PIC) framework. Treatment is individually tailored and may be adjusted according to the participant's needs and response.

Repeated measurements of "How much has CRPS interfered with your daily activities during the past 24 hours?" and "How severe has your average pain been during the past 24 hours?" are collected throughout the study to evaluate changes within each participant and their temporal relationship to the introduction and adjustment of treatment. Validated measures of upper- or lower-limb function (QuickDASH or LEFS) are also collected repeatedly.

Additional standardized questionnaires are administered at baseline and 12 months to characterize the participants and to assess factors that may be associated with clinical and neuroimaging outcomes. These include measures of insomnia (ISI), psychological distress (HSCL-25), pain catastrophizing (PCS), self-efficacy (GSE), fatigue (CFQ), body perception disturbance (Bath CRPS Body Perception Disturbance Scale), neglect-like symptoms, and health-related quality of life (EQ-5D-5L).

Quantitative sensory testing (QST) is conducted to characterize sensory function, including thermal detection and pain thresholds. Neuropsychological testing is conducted to characterize general cognitive abilities, sustained attention, impulsivity, visuomotor reaction time, and executive functioning.

Work Package 2 (WP2) investigates brain structure and its relationship to CRPS using magnetic resonance imaging (MRI). MRI is performed at baseline and after 12 months. Structural brain characteristics, including gray matter morphology and white matter microstructure, in participants with CRPS will be compared with those of healthy controls. Longitudinal MRI will also be used to investigate structural brain changes over time in participants with CRPS and whether these changes are associated with limb function and pain intensity.

Together, the two work packages aim to improve understanding of individual clinical responses to rehabilitation and of structural brain characteristics and their potential changes over time in CRPS.

02

Conditions studied

  • Complex Regional Pain Syndrome (CRPS)

Keywords

  • Complex Regional Pain Syndrome, CRPS, SCED, Graded Motor Imagery, Tactile Desensitization, Psychologically Informed Care, MRI
03

In context

Complex Regional Pain Syndromes

205 studies on the registry are indexed under Complex Regional Pain Syndromes; 55 are open to participants now.

This study's planned enrollment of 12 is below the median of 40 across 152 interventional studies indexed under Complex Regional Pain Syndromes.

Browse Complex Regional Pain Syndromes studies →

Lead sponsor

University Hospital of North Norway is the lead sponsor of 152 studies on the registry; 24 are open to participants now.

Browse University Hospital of North Norway studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older. For participants included in WP2 (MRI), the maximum age is 70 years.
  • Diagnosis of Complex Regional Pain Syndrome (CRPS) according to the Budapest criteria.
  • CRPS affecting a single upper or lower limb.
  • Triggering trauma or onset of pain more than 3 months before inclusion.

Exclusion criteria

Exclusion Criteria:

  • Drug abuse.
  • Malignant or progressive disease, systemic disease, or neurodegenerative disease.
  • Other severe pain conditions.
  • Severe anxiety or depression.
  • Disabling fatigue or myalgic encephalomyelitis (ME).
  • Use of opioid medication exceeding 100 mg oral morphine equivalents (OMEQ).

Additional Exclusion Criteria for WP2 (MRI):

  • History of seizures.
  • Neurological or neurosurgical disorders.
  • Significant cardiac or systemic illness.
  • Implanted metallic or electronic devices incompatible with MRI.
  • Diagnosis of a developmental disorder.
  • Current use of antipsychotic medications, benzodiazepines, or other pharmacological agents that may influence MRI measurements.
  • Pregnancy or lactation.
  • Phobia of MRI examination.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Individualized CRPS Rehabilitation

    Participants receive an individually tailored rehabilitation intervention combining Graded Motor Imagery (GMI) and tactile desensitization (TD) within a Psychologically Informed Care (PIC) framework. The intervention is adapted according to individual needs, treatment response, and progression throughout the rehabilitation period.

    Behavioral: Individualized CRPS Rehabilitation

Interventions

  • BehavioralIndividualized CRPS Rehabilitation

    The rehabilitation intervention combines Graded Motor Imagery (GMI) and tactile desensitization (TD) within a Psychologically Informed Care (PIC) framework. Treatment is individually tailored and adjusted according to the participant's needs, treatment response, and progression throughout the rehabilitation period. GMI includes left/right discrimination training, motor imagery, and mirror therapy. The components are introduced and progressed flexibly according to the participant's individual abilities and response to treatment. Tactile desensitization aims to reduce sensory hypersensitivity and improve tolerance of sensory input through repeated and gradually progressed tactile stimulation of the affected area using different materials and stimuli. The PIC framework integrates physical rehabilitation with psychological principles and strategies addressing cognitive, emotional, and behavioral factors relevant to pain, movement, and daily functioning. The specific treatment components

06

What researchers measure

Primary outcomes

  1. CRPS interference with daily activities

    Participant-reported CRPS interference with daily activities, assessed using a single-item 0-10 Numeric Rating Scale (NRS): "How much has CRPS interfered with your daily activities during the past 24 hours?" Higher scores indicate greater interference (0 = not at all; 10 = to a very great extent). Repeated measurements are collected throughout the baseline and intervention phases as the primary target variable in the multiple-baseline single-case experimental design.

    Time frame: Throughout the baseline and intervention phases, up to 12 months

Secondary outcomes

  1. Average pain intensity

    Participant-reported average pain intensity during the past 24 hours, assessed using a single-item 0-10 Numeric Rating Scale (NRS): "How severe has your average pain been during the past 24 hours?" The NRS ranges from 0 (no pain) to 10 (worst pain imaginable), with higher scores indicating greater pain intensity. Repeated measurements are collected throughout the baseline and intervention phases.

    Time frame: Throughout the baseline and intervention phases, up to 12 months

  2. Lower extremity function (LEFS)

    Lower extremity function assessed using the Lower Extremity Functional Scale (LEFS) in participants with CRPS affecting the lower extremity. The LEFS consists of 20 items assessing difficulty in performing everyday activities. Each item is scored from 0 to 4, giving a total score ranging from 0 to 80, with higher scores indicating better lower extremity function. The LEFS is assessed repeatedly throughout the study.

    Time frame: Repeatedly throughout the baseline and intervention phases, up to 12 months

  3. Upper extremity function (QuickDASH)

    Upper extremity function assessed using the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) questionnaire in participants with CRPS affecting the upper extremity. The QuickDASH consists of 11 items assessing difficulty in performing activities and the impact of upper extremity symptoms. The total score ranges from 0 to 100, with higher scores indicating greater disability. The QuickDASH is assessed repeatedly throughout the study.

    Time frame: Repeatedly throughout the baseline and intervention phases, up to 12 months

  4. CRPS severity (CRPS Severity Score)

    CRPS severity assessed using the CRPS Severity Score (CSS), which comprises 16 clinical signs and symptoms of CRPS. Each item is scored as present (1) or absent (0), resulting in a total score ranging from 0 to 16, with higher scores indicating greater CRPS severity.

    Time frame: Baseline and 12 months

  5. Gray matter brain morphology

    Gray matter brain morphology assessed from structural MRI using FreeSurfer. MRI-derived measures in participants with CRPS will be compared with those of healthy controls at baseline. Longitudinal changes in participants with CRPS will also be assessed from baseline to 12 months.

    Time frame: Baseline and 12 months

  6. White matter microstructure

    White matter microstructure assessed using diffusion tensor imaging (DTI), including fractional anisotropy (FA), mean diffusivity (MD), and radial diffusivity (RD). White matter measures in participants with CRPS will be compared with those of healthy controls at baseline. Longitudinal changes in white matter microstructure will also be assessed in participants with CRPS from baseline to 12 months.

    Time frame: Baseline and 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Krogstad IF, Danielsson L, Danielsson LP, Kvarstein G, Bergvik S. Patients' Experiences With Complex Regional Pain Syndrome (CRPS) and a Rehabilitation Program That Combines Graded Motor Imagery (GMI) and Tactile Desensitization (TD). Pain Res Manag. 2026;2026(1):e4480549. doi: 10.1155/prm/4480549. PubMed 41925129 ↗
  • Smart KM, Ferraro MC, Wand BM, O'Connell NE. Physiotherapy for pain and disability in adults with complex regional pain syndrome (CRPS) types I and II. Cochrane Database Syst Rev. 2022 May 17;5(5):CD010853. doi: 10.1002/14651858.CD010853.pub3. PubMed 35579382 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2016 (actual). Primary completion is estimated for May 2030, 164 months after the start.

Of 64 non-industry interventional studies with no phase under Complex Regional Pain Syndromes, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 60. This study's planned 164 months is above that.

Counting every sponsor, half of 65 studies reached it within 24 months; a quarter within 14 and three quarters within 60.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Dec 2023 → May 2030 and completion Dec 2024 → Nov 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2016
First posted
Apr 27, 2016
StartActual
Sep 2016
Primary completionEst.
May 2030was Dec 2023
CompletionEst.
Nov 15, 2032was Dec 2024
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2023→May 2030
Oct 8, 2026
Study completion
Dec 2024→Nov 15, 2032
Oct 8, 2026
Enrollment
42→12
Oct 8, 2026
Eligibility
1 inclusion criterion edited, 3 added, 3 removed; 3 exclusion criteria edited, 10 added, 4 removed
What changed in the criteria
Inclusion criteria
  • RemovedPatients 18 - 70 years old. For patients who only participate in the clinical RCT (without fMRI) no upper age limit.
  • RemovedCRPS affecting one single upper or lower limb diagnosed by the IASP (2012) Budapest research criteria (Harden et al., 2010).
  • AddedAge 18 years or older. For participants included in WP2 (MRI), the maximum age is 70 years.
  • AddedDiagnosis of Complex Regional Pain Syndrome (CRPS) according to the Budapest criteria.
  • AddedCRPS affecting a single upper or lower limb.
  • EditedTriggering trauma or the onset of pain >more than 3 months agobefore inclusion.
  • RemovedIf possible drugs that can influence the fMRI scans should be avoided. Documentation if used.
Exclusion criteria
  • EditedMalignant/ or progressive disease, systemic disease, or neurodegenerative disease.
  • RemovedSevere clinical anxiety or depression, symptoms of fatigue or ME of a disabling level.
  • RemovedFor patients who participate in the MRI related analyses:
  • RemovedMetallic implants incompatible with the MR technology or medical condition not recommended for fMRI.
  • AddedSevere anxiety or depression.
  • AddedDisabling fatigue or myalgic encephalomyelitis (ME).
  • AddedUse of opioid medication exceeding 100 mg oral morphine equivalents (OMEQ).
  • AddedAdditional Exclusion Criteria for WP2 (MRI):
  • AddedHistory of seizures.
  • AddedNeurological or neurosurgical disorders.
  • AddedSignificant cardiac or systemic illness.
  • AddedImplanted metallic or electronic devices incompatible with MRI.
  • AddedDiagnosis of a developmental disorder.
  • AddedCurrent use of antipsychotic medications, benzodiazepines, or other pharmacological agents that may influence MRI measurements.
  • EditedPregnancy or lactation.
  • EditedPhobia forof MRI examination.
  • RemovedDiseases that can cause structural changes and interfere with the interpretation of the MRI-scans (like severe diabetes mellitus, heart disease, ischemic stroke and vascular conditions).
Oct 8, 2026
Interventions
Added Behavioral: Individualized CRPS Rehabilitation; removed Behavioral: GMI and Desensitization·Behavioral: Desensitization. Arms added: Individualized CRPS Rehabilitation; arms removed: GMI and Desensitization·Desensitization
Oct 8, 2026
Primary outcomes
1 added, 2 removed
What changed in the outcomes
  • AddedCRPS interference with daily activitiesTime frame: Throughout the baseline and intervention phases, up to 12 months
  • RemovedGroup difference in pain intensityTime frame: 6 weeks after baseline
  • RemovedChange from baseline in intra-network connectivity in the Default Mode NetworkTime frame: 6 months after baseline
Oct 8, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41925129 ↗
Oct 8, 2026
Secondary outcomes
6 added, 15 removed
What changed in the outcomes
  • AddedAverage pain intensityTime frame: Throughout the baseline and intervention phases, up to 12 months
  • AddedLower extremity function (LEFS)Time frame: Repeatedly throughout the baseline and intervention phases, up to 12 months
  • AddedUpper extremity function (QuickDASH)Time frame: Repeatedly throughout the baseline and intervention phases, up to 12 months
  • AddedCRPS severity (CRPS Severity Score)Time frame: Baseline and 12 months
  • AddedGray matter brain morphologyTime frame: Baseline and 12 months
  • AddedWhite matter microstructureTime frame: Baseline and 12 months
  • RemovedChange from baseline in pain intensityTime frame: 6 weeks after baseline
  • RemovedChange from baseline in pain intensityTime frame: 6 months after baseline
  • RemovedChange from baseline in pain intensityTime frame: 12 months after baseline
  • RemovedGroup difference in CRPS Severity ScoreTime frame: 6 weeks after baseline
  • RemovedChange from baseline in CRPS Severity ScoreTime frame: 6 weeks after baseline
  • RemovedChange from baseline in CRPS Severity ScoreTime frame: 6 months after baseline
  • RemovedChange from baseline in CRPS Severity ScoreTime frame: 12 months after baseline
  • RemovedGroup difference in Quick DASH score/percent lower extremity functional scale scoreTime frame: 6 weeks after baseline
  • RemovedRelative change from baseline in Quick DASH/Lower extremity functional scale scoreTime frame: 6 weeks after baseline
  • RemovedRelative change from baseline in Quick DASH/Lower extremity functional scale scoreTime frame: 6 months after baseline
  • RemovedRelative change from baseline in Quick DASH/Lower extremity functional scale scoreTime frame: 12 months after baseline
  • RemovedGroup difference in responder rateTime frame: 6 weeks after baseline
  • RemovedChange from baseline in responder rateTime frame: 6 weeks after baseline
  • RemovedChange from baseline in responder rateTime frame: 6 months after baseline
  • RemovedChange from baseline in responder rateTime frame: 12 months after baseline
Oct 8, 2026
Contact
Study contact changed: g•••@uit.no→l•••@unn.no; l•••@unn.no→G•••@uit.no. See the current contact
Oct 8, 2026
Title
A Comparison of Two Treatments for CRPS and Changes in Resting-State Connectivity of Cerebral Networks.→Clinical and Cerebral Changes Following Multifaceted Rehabilitation of Complex Regional Pain Syndrome
Oct 8, 2026
Sponsor
University of Tromso→University Hospital of North Norway; Collaborators added: UiT The Arctic University of Norway·Örebro University, Sweden·The Royal Norwegian Ministry of Health·University of Liverpool; collaborators removed: University Hospital of North Norway
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41925129 ↗
    Primary completion Dec 2023→May 2030
    Study completion Dec 2024→Nov 15, 2032
    Enrollment 42→12
    Eligibility 1 inclusion criterion edited, 3 added, 3 removed; 3 exclusion criteria edited, 10 added, 4 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedPatients 18 - 70 years old. For patients who only participate in the clinical RCT (without fMRI) no upper age limit.
    • RemovedCRPS affecting one single upper or lower limb diagnosed by the IASP (2012) Budapest research criteria (Harden et al., 2010).
    • AddedAge 18 years or older. For participants included in WP2 (MRI), the maximum age is 70 years.
    • AddedDiagnosis of Complex Regional Pain Syndrome (CRPS) according to the Budapest criteria.
    • AddedCRPS affecting a single upper or lower limb.
    • EditedTriggering trauma or the onset of pain >more than 3 months agobefore inclusion.
    • RemovedIf possible drugs that can influence the fMRI scans should be avoided. Documentation if used.
    Exclusion criteria
    • EditedMalignant/ or progressive disease, systemic disease, or neurodegenerative disease.
    • RemovedSevere clinical anxiety or depression, symptoms of fatigue or ME of a disabling level.
    • RemovedFor patients who participate in the MRI related analyses:
    • RemovedMetallic implants incompatible with the MR technology or medical condition not recommended for fMRI.
    • AddedSevere anxiety or depression.
    • AddedDisabling fatigue or myalgic encephalomyelitis (ME).
    • AddedUse of opioid medication exceeding 100 mg oral morphine equivalents (OMEQ).
    • AddedAdditional Exclusion Criteria for WP2 (MRI):
    • AddedHistory of seizures.
    • AddedNeurological or neurosurgical disorders.
    • AddedSignificant cardiac or systemic illness.
    • AddedImplanted metallic or electronic devices incompatible with MRI.
    • AddedDiagnosis of a developmental disorder.
    • AddedCurrent use of antipsychotic medications, benzodiazepines, or other pharmacological agents that may influence MRI measurements.
    • EditedPregnancy or lactation.
    • EditedPhobia forof MRI examination.
    • RemovedDiseases that can cause structural changes and interfere with the interpretation of the MRI-scans (like severe diabetes mellitus, heart disease, ischemic stroke and vascular conditions).
    Primary outcomes 1 added, 2 removed
    What changed in the outcomes
    • AddedCRPS interference with daily activitiesTime frame: Throughout the baseline and intervention phases, up to 12 months
    • RemovedGroup difference in pain intensityTime frame: 6 weeks after baseline
    • RemovedChange from baseline in intra-network connectivity in the Default Mode NetworkTime frame: 6 months after baseline
    Secondary outcomes 6 added, 15 removed
    What changed in the outcomes
    • AddedAverage pain intensityTime frame: Throughout the baseline and intervention phases, up to 12 months
    • AddedLower extremity function (LEFS)Time frame: Repeatedly throughout the baseline and intervention phases, up to 12 months
    • AddedUpper extremity function (QuickDASH)Time frame: Repeatedly throughout the baseline and intervention phases, up to 12 months
    • AddedCRPS severity (CRPS Severity Score)Time frame: Baseline and 12 months
    • AddedGray matter brain morphologyTime frame: Baseline and 12 months
    • AddedWhite matter microstructureTime frame: Baseline and 12 months
    • RemovedChange from baseline in pain intensityTime frame: 6 weeks after baseline
    • RemovedChange from baseline in pain intensityTime frame: 6 months after baseline
    • RemovedChange from baseline in pain intensityTime frame: 12 months after baseline
    • RemovedGroup difference in CRPS Severity ScoreTime frame: 6 weeks after baseline
    • RemovedChange from baseline in CRPS Severity ScoreTime frame: 6 weeks after baseline
    • RemovedChange from baseline in CRPS Severity ScoreTime frame: 6 months after baseline
    • RemovedChange from baseline in CRPS Severity ScoreTime frame: 12 months after baseline
    • RemovedGroup difference in Quick DASH score/percent lower extremity functional scale scoreTime frame: 6 weeks after baseline
    • RemovedRelative change from baseline in Quick DASH/Lower extremity functional scale scoreTime frame: 6 weeks after baseline
    • RemovedRelative change from baseline in Quick DASH/Lower extremity functional scale scoreTime frame: 6 months after baseline
    • RemovedRelative change from baseline in Quick DASH/Lower extremity functional scale scoreTime frame: 12 months after baseline
    • RemovedGroup difference in responder rateTime frame: 6 weeks after baseline
    • RemovedChange from baseline in responder rateTime frame: 6 weeks after baseline
    • RemovedChange from baseline in responder rateTime frame: 6 months after baseline
    • RemovedChange from baseline in responder rateTime frame: 12 months after baseline
    Interventions Added Behavioral: Individualized CRPS Rehabilitation; removed Behavioral: GMI and Desensitization·Behavioral: Desensitization. Arms added: Individualized CRPS Rehabilitation; arms removed: GMI and Desensitization·Desensitization
    Sponsor University of Tromso→University Hospital of North Norway; Collaborators added: UiT The Arctic University of Norway·Örebro University, Sweden·The Royal Norwegian Ministry of Health·University of Liverpool; collaborators removed: University Hospital of North Norway
    Contact Study contact changed: g•••@uit.no→l•••@unn.no; l•••@unn.no→G•••@uit.no. See the current contact
    Title A Comparison of Two Treatments for CRPS and Changes in Resting-State Connectivity of Cerebral Networks.→Clinical and Cerebral Changes Following Multifaceted Rehabilitation of Complex Regional Pain Syndrome
    + 6 other changes: verification date, oversight details, description, conditions, design details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02753335
Lead sponsor
University Hospital of North Norway
Collaborators
UiT The Arctic University of Norway, Örebro University, Sweden, The Royal Norwegian Ministry of Health, University of Liverpool
Responsible party
Sponsor
First posted
Apr 27, 2016
Start date
Sep 2016
Primary completion
May 2030 (estimated)
Completion
Nov 15, 2032 (estimated)
Last update
Oct 8, 2026

Study contacts

Lena Danielsson, PhD
Contact
lena.danielsson@unn.no
Kvarstein Gunnvald, PhD
Contact
Gunnvald.Kvarstein@uit.no
Lena Danielsson, PhD
study director · University Hospital og North Norway

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Complex Regional Pain Syndromes →

Other studies from this sponsor

University Hospital of North Norway →

Start the discussion